Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia: A systematic review and meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia : A systematic review and meta-analysis. / Laumann, Renate Dagsdottir; Pedersen, Louise Lindkvist; Andrés-Jensen, Liv; Mølgaard, Christian; Schmiegelow, Kjeld; Frandsen, Thomas Leth; Als-Nielsen, Bodil.
I: Pediatric Blood and Cancer, Bind 70, Nr. 12, e30683, 2023.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia
T2 - A systematic review and meta-analysis
AU - Laumann, Renate Dagsdottir
AU - Pedersen, Louise Lindkvist
AU - Andrés-Jensen, Liv
AU - Mølgaard, Christian
AU - Schmiegelow, Kjeld
AU - Frandsen, Thomas Leth
AU - Als-Nielsen, Bodil
N1 - Publisher Copyright: © 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
PY - 2023
Y1 - 2023
N2 - Background: The established association between acute lymphoblastic leukemia (ALL) and hyperlipidemia has, in some studies, been linked to toxicities such as pancreatitis, thrombosis, and osteonecrosis. However, a systematic review investigating the incidence, management, and clinical implications of hyperlipidemia during childhood ALL treatment is lacking. Objectives: Systematically assess the incidence of hyperlipidemia during ALL treatment, explore associations with risk factors and severe toxicities (osteonecrosis, thrombosis, and pancreatitis), and review prevalent management strategies. Methods: A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Data synthesis was descriptive, and a meta-analysis of hypertriglyceridemia and risk of severe toxicities was performed. Results: We included 13 studies with 3,425 patients. Hyperlipidemia incidence varied widely (6.7%-85%) but with inconsistent definitions and screening strategies across studies. Evidence regarding risk factors was conflicting, but age (> 10 years) and treatment with asparaginase and glucocorticosteroids seem to be associated with hyperlipidemia. Hypertriglyceridemia (grade 3/4) increased the risk for osteonecrosis (odds ratio (OR): 4.27, 95% confidence interval (CI): 2.77-6.61). No association could be established for pancreatitis (OR: 1.60, 95% CI: 0.53-4.82) or thrombosis (OR: 2.45, 95% CI: 0.86-7.01), but larger studies are needed to confirm this. Conclusion: The overall evidence of this systematic review is limited by the small number of studies and risk of bias. Our review suggests that hypertriglyceridemia increases the risk for osteonecrosis. However, larger studies are needed to explore the clinical implications of hyperlipidemia and randomized trials investigating hyperlipidemia management and its impact on severe toxicities.
AB - Background: The established association between acute lymphoblastic leukemia (ALL) and hyperlipidemia has, in some studies, been linked to toxicities such as pancreatitis, thrombosis, and osteonecrosis. However, a systematic review investigating the incidence, management, and clinical implications of hyperlipidemia during childhood ALL treatment is lacking. Objectives: Systematically assess the incidence of hyperlipidemia during ALL treatment, explore associations with risk factors and severe toxicities (osteonecrosis, thrombosis, and pancreatitis), and review prevalent management strategies. Methods: A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Data synthesis was descriptive, and a meta-analysis of hypertriglyceridemia and risk of severe toxicities was performed. Results: We included 13 studies with 3,425 patients. Hyperlipidemia incidence varied widely (6.7%-85%) but with inconsistent definitions and screening strategies across studies. Evidence regarding risk factors was conflicting, but age (> 10 years) and treatment with asparaginase and glucocorticosteroids seem to be associated with hyperlipidemia. Hypertriglyceridemia (grade 3/4) increased the risk for osteonecrosis (odds ratio (OR): 4.27, 95% confidence interval (CI): 2.77-6.61). No association could be established for pancreatitis (OR: 1.60, 95% CI: 0.53-4.82) or thrombosis (OR: 2.45, 95% CI: 0.86-7.01), but larger studies are needed to confirm this. Conclusion: The overall evidence of this systematic review is limited by the small number of studies and risk of bias. Our review suggests that hypertriglyceridemia increases the risk for osteonecrosis. However, larger studies are needed to explore the clinical implications of hyperlipidemia and randomized trials investigating hyperlipidemia management and its impact on severe toxicities.
KW - Acute lymphoblastic leukemia
KW - hyperlipidemia
KW - pediatrics
KW - toxicities
U2 - 10.1002/pbc.30683
DO - 10.1002/pbc.30683
M3 - Review
C2 - 37776083
AN - SCOPUS:85173517542
VL - 70
JO - Medical and Pediatric Oncology. Supplement
JF - Medical and Pediatric Oncology. Supplement
SN - 0740-8226
IS - 12
M1 - e30683
ER -
ID: 376307814